Cancer

Profound Medical Announces Pricing of US$20 Million Public Offering of Common Shares

TORONTO, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”) today announced the pricing…

12 months ago

Profound Medical Announces Proposed Public Offering of Common Shares

TORONTO, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”) is pleased to announce…

12 months ago

Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference

SEATTLE, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to…

12 months ago

Cosmos Health Set for Substantial Growth From Acquisitions Completed in 2023

In 2023, Cosmos Health concluded multiple acquisitions, including Cana Laboratories, the distribution network owned by Bikas GP, and ZipDoctor.These acquisitions…

1 year ago

Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108

Company to retain economic interest in biotherapeutic asset while removing cash burn from development and commercialization costsREDWOOD CITY, Calif., Dec.…

1 year ago

Beyond Cancer™ Phase 1 Study Clears Cohort 1 in Patients with Advanced Relapsed or Refractory Unresectable Primary or Metastatic Cutaneous or Subcutaneous Solid Tumors

No dose limiting toxicities were reported in the first cohort of ultra-high concentration of nitric oxide administered at 25,000 parts…

1 year ago

Iovance Biotherapeutics Announces Clinical Program Update for LN-145 in Non-Small Cell Lung Cancer

SAN CARLOS, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating,…

1 year ago

First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program

First Wave BioPharma to advance GI development pipeline with the expected addition of Phase 3 Latiglutenase celiac disease program and…

1 year ago

NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208

ORION CORPORATION PRESS RELEASE 27 DECEMBER 2023 at 11:00 EET                      NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208…

1 year ago